Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in marketing medicines for eye diseases, colorectal cancer and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma and atopic dermatitis. Its products include EYLEA injection, which is used for the treatment of neovascular age related macular degeneration; ARCALYST, which is used for the treatment of Cryopyrin-Associated Periodic Syndrome, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome; and PRALUENT Injection for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C. Regeneron Pharmaceuticals was founded by Alferd G. Gilman, Leonard S. Schleifer and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
|Market Price at 20-10-2017
|Price to Earnings Ratio
|Return on Equity (ROE)
Blog posts that reference Regeneron Pharmaceuticals:
Friday, September 02, 2016
Opportunities are there for those who wish to seek them out. Another seven companies attained A1 status this week and eighteen stocks meet our Top Stocks criteria. Read about two of the new A1 stocks, plumbing and bathroom products supplier Reece (REH), and student placement and IELTS provider IDP Education (IEL).
Friday, August 26, 2016
This week many companies released their 2016 reports. We focus in on two big movers. Sirtex Medical gained 12% following a strong result and regained its A1 status. Blackmores fell 23% despite a strong result also retaining its A1 score. Read more to understand why.
Friday, August 19, 2016
Over the last week a number of big name companies were updated in Skaffold including BHP Billiton, Telstra, Mirvac and QBE. Some other popular stocks that reported this week included JB Hi-Fi, Dominos and Magellan Financial Group. Also discussed a video are REA Group, JB Hi-Fi and Nick Scali.
Friday, August 12, 2016
This week saw a lot more action on the reporting season calendar. Whilst there were a few pleasing performances there were few gold medals. The only company to ascend the podium to A1 status was Tamawood, a designer and builder of residential homes. Tamawood is a small company of $90 million market cap and no analyst coverage. It has generated good profit growth over the last few years however the cash funding falls a bit short, resulting in a funding deficit.
Friday, August 05, 2016
The last 12 months have been one crazy ride on the markets as the mood has swung wildly from optimism to pessimism and back again. Over the last 12 months the S&P/ASX 300 has fallen 3.4%, but in February it was down 16%, and has since then rallied 15% to today’s levels.
Tuesday, June 21, 2016
After the Top 20 blue chip stocks on the ASX have had a return of only 1.9% over the past year compared to the 19.9% of the next 180 largest stocks, AFR last month asked Skaffold’s General Manager, Chris Batchelor to come up with six blue chip stocks that exhibit the qualities investors should seek for long term outperformance (blue chips of the future)
Tuesday, May 24, 2016
Skaffold recently added a further 10 stocks to the Swiss market taking the total Swiss stocks covered to almost 50. Switzerland is a small stock market, but it includes some of the world’s largest and most profitable companies.
Friday, February 12, 2016
There has been a lot more activity with companies reporting this week. A few highlights included Class (CODE:CL1) went from A2 to A1, Nick Scali (CODE:NCK) and JB Hi Fi (CODE:JBH) retained their A1 status and REA Group (CODE:REA) remained an A2. Capilano Honey (CODE:CZZ) lost its A1 status, slumping to A3.
Tuesday, December 01, 2015
Roger Montgomery and Chris Batchelor reveal six top stocks set to deliver outstanding growth in 2016. They give quick analyses as to why they have picked these stocks and then finally the webinar attendees voted for one of the stocks for Roger and Chris to drill down. Roger picked Challenger (CGF), REA Group (REA) and Apple (AAPL) while Chris picked Breville (BRG), Navitas (NVT) and Amalgamated Holdings Limited (AHD). Find out who the audience voted for.
Saturday, November 21, 2015
After an uncertainty-filled 2015, building a strong portfolio that will safeguard your investment in 2016 is crucial.
At Skaffold’s latest webinar Roger Montgomery and Chris Batchelor revealed how they plan to invest in 2016. They shared what global trends to look out for, and the rules they put in place to successfully manage their portfolios.
Roger and Chris also revealed:
• How they apply the principles of diversification
• The optimal number of stocks to own for investors with $20k, $50, $100k and $500k to invest
• How long to hold shares for, and when to sell
• The biggest challenges facing SMSF investors in 2016
The highlight of session was Roger and Chris’ take on REA Group. Where will future growth come from, and is this a stock to buy?